Molomics

Molomics, founded in 2015, operated as a drug discovery and development company from its base in the Barcelona Science Park until its acquisition by VeriSIM Life in May 2022. The founding team consisted of CEO Jascha Blobel, Chief Scientific Officer (CSO) Giovanni Cincilla, and Chief Technology Officer (CTO) Simone Masoni. Blobel, who holds a PhD in Biochemistry, brought five years of pharmaceutical business development experience to the venture, driven by a goal to create a next-generation AI biotech company. The founders retained a majority of the company's capital, enabling agile execution of their business plan.

The company developed a patented technology that uniquely integrated artificial intelligence (AI) with human collective intelligence (HCI) to design novel small-molecule therapeutics. This proprietary, cloud-based platform allowed scientific specialists to collaboratively design and optimize drug candidates in real-time, aiming to create safer and more effective treatments. By combining machine learning predictions with human expertise, Molomics sought to reduce the high failure rate and associated costs of drug development, which can save pharmaceutical companies hundreds of millions of euros per project. The firm's business model focused on leveraging its platform to generate a pipeline of drug candidates and form co-development or licensing agreements with pharmaceutical companies. One of its key projects involved advancing a treatment for Parkinson's disease, specifically targeting levodopa-induced dyskinesia, which gained support from the Michael J. Fox Foundation.

Prior to its acquisition, Molomics had raised over €1 million in public and private capital. In May 2022, US-based VeriSIM Life acquired Molomics for an undisclosed amount, paid in VeriSIM Life shares. The deal involved integrating Molomics' technology into VeriSIM's BIOiSIM™ virtual drug development engine to enhance the discovery and development of treatments for neurological, oncological, and other life-threatening diseases. The founding team did not join VeriSIM Life, opting to pursue new projects.

Keywords: drug discovery, artificial intelligence, human collective intelligence, small-molecule therapeutics, Parkinson's disease, computational drug design, biotech, pharmaceutical R&D, machine learning, in silico design, Barcelona, drug development, therapeutic molecules, VeriSIM Life, Jascha Blobel, Giovanni Cincilla, Simone Masoni, deep tech, virtual drug development, BIOiSIM